Mark Hopman, Chief Commercial Officer at Beta Bionics, Inc. (BBNX), sold 5,834 shares at $29.34 ($177K) on 2025-12-02, disclosed to the SEC on 2026-03-16.
Scheduled sale ($177k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.34 | 856 | $25K | 14.2% |
| 2 | $29.34 | 856 | $25K | 14.2% |
| 3 | $30.66 | 2,061 | $63K | 35.8% |
| 4 | $30.66 | 2,061 | $63K | 35.8% |
| Total | $30.27 avg | 5,834 | $177K | 100% |
| Filing → |
| BBNX | SELL | 2026-09-18 | $665K | — | Filing → |
| BBNX | SELL | 2026-09-17 | $620K | — | Filing → |
| BBNX | SELL | 2026-09-15 | $12K | — | Filing → |